Vir Biotechnology (VIR) Stock Soars on Early Omicron Testing Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Vir Biotechnology (VIR) PT Raised to $200 at H.C. Wainwright
November 30, 2021 9:17 AM ESTH.C. Wainwright analyst Patrick Trucchio raised the price target on Vir Biotechnology (NASDAQ: VIR) to $200.00 (from $135.00) while maintaining a Buy rating.
The analyst commented, "Several recent updates suggest to us that Vir and its collaboration partner GlaxoSmithKline (GSK; not rated) are likely to maintain a top-tier COVID-19 antiviral franchise, led at first by sotrovimab, an FDA EUA-authorized investigational single-dose intravenous (IV) infusion SARS-CoV-2 monoclonal antibody (mAb), for the foreseeable future including: (1) on November 26, the... More
